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DETERMINING DISEASE CAUSALITY 
FROM EXPERIMENTAL TOXICOLOGY 
STUDIES 
Ronald L. Melnick, Ph.D. and  
John R. Bucher, Ph.D.∗ 
INTRODUCTION 
In contrast to attempts by journals and scientific review 
panels to reveal and/or limit conflicts of interest in scientific 
publications and peer review evaluations,1 conflicts of interest 
are an inherent component of science-based litigation, and 
generally include presentations and interpretations of studies that 
are fashioned to appear consistent and favorable to the position 
of the sponsoring party.2 This situation puts an enormous burden 
on judges and juries, forcing them to wade through disguised 
biases in order to decipher assertions from facts. Numerous 
conflicts have and continue to arise over the reliability and 
interpretation of health effects research data because of 
uncertainties in the precise extrapolation of adverse effects 
observed in experimental animals to individual human risk and 
in the costs and benefits associated with reduction or elimination 
                                                          
∗ Ronald L. Melnick is Director of Special Programs, Environmental 
Toxicology Program (ETP), National Toxicology Program (NTP), National 
Institute of Environmental Health Sciences (NIEHS); John R. Bucher is 
Deputy Director ETP, NTP/NIEHS. 
1 See, e.g., Frank Davidoff et al., Sponsorship, Authorship, and 
Accountability, 345 N. ENG. J. MED. 825, 825-27 (2001); Vincent James 
Cogliano et al., The Science and Practice of Carcinogen Identification and 
Evaluation, 112 ENVTL. HEALTH PERSP. 1269, 1269-74 (2004). 
2 See, e.g., Wendy Wagner, The Perils of Relying on Interested Parties 
to Evaluate Scientific Quality. 95 Am. J. Pub. Health S99, S99-S106 (2005). 
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of human exposures to toxic agents.3 Conflicting opinions on the 
utility of data obtained from studies in laboratory animals seem 
to originate largely from concerns of impacts of exposures on 
human health versus impacts on costs and profits.4 
Although science seeks to expand our knowledge of facts and 
truths through the principles of hypothesis generation and 
hypothesis testing, the way in which our knowledge grows and 
reflects the truth depends on how questions are framed, how 
rigorously hypotheses are tested, and to what extent assertions 
extend beyond actual findings and are portrayed as established 
facts. This paper focuses on principles of design and evaluation 
of animal carcinogenicity studies and the utility of these studies 
for determining disease causality and estimating human cancer 
risk. Part I will discuss the use of animal studies in the context 
of public health decisions. Part II will examine issues concerning 
the design of experimental studies. Part III will explore issues 
relating to how experimental studies are evaluated and Part IV 
will explore issues concerning the assessment of human cancer 
risk based on results from animal experimentation. 
I.  USE OF ANIMAL STUDIES FOR PUBLIC HEALTH DECISIONS 
In 1978, the Department of Health Education and Welfare 
(now the Department of Health and Human Services) created the 
National Toxicology Program (NTP), an interagency resource to 
coordinate toxicology testing programs within the federal 
government.5 The mission of the NTP is to strengthen the 
scientific basis for risk assessments, develop and validate 
improved testing methods, and provide information about 
potentially toxic chemicals to health, regulatory, and research 
                                                          
3 Ronald L. Melnick, A Daubert Motion–A Legal Strategy to Exclude 
Essential Scientific Evidence in Toxic Tort Litigation, 95 Am. J. Pub. Health 
S30, S30-S34 (2005). 
4 Laura Heinzerling & Frank Ackerman, Pricing the Priceless: Cost-
Benefit Analysis of Environmental Protection, GEO. ENVTL. L & POL’Y INST., 
GEO. U.L. CENTER (2002). 
5 J.A. Califano, Establishment of a National Toxicology Program, 
Federal Reg. 43, 53080-53081 (1978). 
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agencies, the scientific and medical communities, and the 
public.6 Since the time of its inception, more than 600 agents 
have been tested for carcinogenic activity in laboratory animals, 
and technical reports of those studies have undergone peer 
review.7 The standardized approaches used by the NTP for the 
evaluation of carcinogenicity of environmental and occupational 
agents are frequently referred to as the gold standard for 
carcinogen identification.8 Congress also mandates that the NTP 
provide and update a list of substances that are “reasonably 
anticipated” or “known” human carcinogens.9 Currently, the 
NTP’s Eleventh Report on Carcinogens lists 246 agents under 
one of these two categories.10 
Why are animal models used to evaluate human risk? The 
most obvious explanation is that it is unethical to test for adverse 
health effects, such as cancer, in humans through intentional 
exposures.11 Just as animal models are used in preclinical trials 
of new pharmaceutical agents before testing in humans, 
experimental studies performed on animals have been used to 
assess potential health risks of toxic and carcinogenic agents in 
our workplace and general environment.12 The predictive value 
of animal studies is based on species similarities in the biological 
processes of disease induction.13 Another major advantage of 
                                                          
6 Id. 
7 See Department of Health and Human Services, The National 
Toxicology Program, http://ntp.niehs.nih.gov (listing toxicology studies). 
8 John R. Bucher, The National Toxicology Program Rodent Bioassay: 
Designs, Interpretations and Scientific Contributions, Annals N.Y. Acad. Sci. 
982, 198-207 (2002). 
9 Public Health Services Act, 42 U.S.C. § 241(b)(4) (1999). 
10 NAT’L TOXICOLOGY PROGRAM, U.S. DEPARTMENT OF HEALTH AND 
HUMAN SERVICES, REPORT ON CARCINOGENS at I-5 (11th ed. 2004). 
11 C. Oleskey et al., Pesticide Testing in Humans: Ethics and Public 
Policy, 112 ENVTL. HEALTH PERSP. 914, 914-19 (2004). 
12 See Environmental Protection Agency, IRIS Database for Risk 
Assessment, available at http://www.epa.gov/iris (containing a database of 
toxicology studies). 
13 H.R. Pohl et al., Risk Assessment of Chemicals and Pharmaceuticals 
in the Pediatric Population: A Workshop Report, 42 REGULATORY 
TOXICOLOGY & PHARMACOLOGY 83, 83-95 (2005); I.H. Russo & J. Russo, 
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animal studies is the elimination of the need to wait for a high 
incidence of human cancers, which may take as much as 30 
years from time of first exposure to clinical manifestation of 
disease, before implementing public health protective 
strategies.14 
Human epidemiology studies typically have limited exposure 
information especially at times early in tumor development, and 
confounding factors are not always known.15 In contrast, 
exposure conditions can be finely controlled in experimental 
studies, making it easier to interpret and assign causality.16 The 
major disadvantages of animal studies are that they require 
extrapolations across species and dose, and they do not capture 
the full range of human susceptibility due to differences in 
genetics, health status, diet, life style, and exposures to other 
agents.17 
Public health agencies, including the International Agency 
for Research on Cancer (IARC),18 NTP,19 and the U.S. 
Environmental Protection Agency (EPA),20 have endorsed the 
perspective that “in the absence of adequate data in humans, it is 
                                                          
Mammary Gland Neoplasia in Long-Term Rodent Studies, 104 ENVTL. 
HEALTH PERSP. 938, 938-67 (1996). 
14 See World Health Organization International Agency for Research on 
Cancer, IARC Monographs on the Evaluation of Carcinogenic Risks to 
Humans, at 14, available at http://monographs.iarc.fr/ENG/Preamble/ 
CurrentPreamble.pdf (last visited Dec. 14, 2006). 
15 L.T. Stayner & R.J. Smith, Methodologic Issues in Using 
Epidemiologic Studies of Occupational Cohorts for Cancer Risk Assessment, 
14 EPIDEMIOL. PREV. 32, 32-39 (1992). 
16 L. Tomatis, Role of Experimental and Epidemiological Evidence of 
Carcinogenicity in the Primary Prevention of Cancer, 42 ANNALI 
DELL’ISTITUTO SUPERIORE DI SANITÀ 113, 113-17 (2006) (Italy). 
17 R.J. Preston, Extrapolations are the Achilles Heel of Risk Assessment, 
589 MUTATION RESEARCH 153, 153-57 (2005). 
18 77 INT’L AGENCY FOR RESEARCH ON CANCER, Di(2-
ethylhexyl)phthalate, in IARC MONOGRAPHS ON THE EVALUATION OF 
CARCINOGENIC RISKS TO HUMANS 41-148 (2000). 
19 NAT’L TOXICOLOGY PROGRAM, supra note 10. 
20 U.S. ENVTL. PROT. AGENCY, PUBL’N NO. EPA/630/P-03/001F, 
GUIDELINES FOR CARCINOGEN RISK ASSESSMENT (2005). 
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biologically plausible and prudent to regard agents and mixtures 
for which there is sufficient evidence of carcinogenicity in 
experimental animals as if they presented a carcinogenic risk to 
humans.” This position is based on the fact that all known 
human carcinogens that have been studied adequately in 
experimental animals produce positive carcinogenic results.21 
Hence, even in the absence of adequate human data, public 
health agencies have classified agents as possibly/probably or 
likely to be carcinogenic to humans22 or reasonably anticipated 
to be a human carcinogen23 if there is sufficient evidence in 
animals demonstrating either (1) increased incidence of 
malignant or malignant and benign tumors combined in two or 
more species or at multiple sites, or (2) increased incidence in 
two or more independent studies in one species, or (3) increased 
incidence in a single study in one species if malignant tumors 
occur to an unusual degree in incidence, site, type, or age of 
onset.24 Several agents that were considered to be possible or 
probable human carcinogens based on animal data were later 
confirmed as human carcinogens when reliable epidemiology 
data (usually occupational exposures) became available (e.g., 
1,3-butadiene, cadmium, diethylstilbestrol, ethylene oxide, 
formaldehyde, and vinyl chloride).25 
                                                          
21 INT’L AGENCY FOR RESEARCH ON CANCER, supra note 18. 
22 INT’L AGENCY FOR RESEARCH ON CANCER, supra note 18; U.S. 
ENVTL. PROT. AGENCY, supra note 20. 
23 NAT’L TOXICOLOGY PROGRAM, supra note 10. 
24 INT’L AGENCY FOR RESEARCH ON CANCER, supra note 18; NATIONAL 
TOXICOLOGY PROGRAM, supra note 10; U.S. ENVTL. PROT. AGENCY, supra 
note 20. 
25 James Huff, Chemicals and Cancer in Humans: First Evidence in 
Experimental Animals, 100 ENVTL. HEALTH PERSP. 201 (1993), available at 
http://www.pubmedcentral.com/picrender.fcgi?artid=1519590&blobtype=pdf 
(last visited Nov. 29, 2006) 
MELNICK 3/3/2007 2:06 AM 
118 JOURNAL OF LAW AND POLICY 
II.  EXPERIMENTAL DESIGN ISSUES 
The design of experimental studies is critical for the 
identification of adverse health effects caused by specific 
environmental agents and the characterization of dose-response 
relationships.26 For example, deficiencies in early studies of 
benzene in animals, which included too few animals, lack of 
controls, short study duration, and low levels of exposure, failed 
to detect carcinogenic effects, even though epidemiology studies 
had demonstrated a causal association between benzene exposure 
and leukemia in humans. Subsequent studies that were better 
designed established benzene as a potent, multi-site carcinogen 
in rats and mice.27 
Experimental design issues that might influence the outcome 
of a carcinogenicity study in laboratory animals are discussed 
below and include the purity and stability of the chemical agent, 
the animal models used, the number of animals per dose group, 
and the exposure levels. 
A.  Chemical 
To ensure that the agent under study is responsible for any 
observed effects and that any contaminants are not the cause or 
modifier of that response, the chemical should be tested at high 
purity. Prior to exposing animals to the agent, it is necessary to 
demonstrate its stability under the conditions of exposure and 
storage. If the agent degrades or evaporates during exposure, the 
accuracy of the targeted administered dose is compromised and 
                                                          
26 See Bucher, supra note 8. 
27 Cesare Maltoni et al., Benzene, an Experimental Multipotential 
Carcinogen: Results of the Long-Term Bioassays Performed at the Bologna 
Institute of Oncology, 82 ENVTL. HEALTH PERSP. 109 (1989), available at 
http://www.pubmedcentral.com/picrender.fcgi?artid=1568122&blobtype=pdf 
(last visited Nov. 29, 2006); J.E. Huff et al., Multiple-Site Carcinogenicity of 
Benzene in Fischer 344 Rats and B6C3F1 Mice, 82 ENVTL. HEALTH PERSP. 
125 (1989), available at http://www.pubmedcentral.com/ 
picrender.fcgi?artid=1568117&blobtype=pdf (last visited Nov. 29, 2006). 
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degradation products may contribute to any observed response. 
For example, a study of trichloroethylene mixed in feed would 
not have reliable exposure data due to the volatile loss of this 
chemical from the feed samples and the potential cross 
contamination of the control groups by inhalation exposure. 
B.  Animal Models 
Rats and mice are the two species most frequently used in 
tests for carcinogenic activity because they have life spans of 
about two-and-a-half years28 and studies of up to 1,000 animals 
can be performed in reasonably sized animal rooms. Strains of 
animal models used should have good longevity, genetic 
stability, and few spontaneous diseases that might shorten their 
life span, mask any chemical induced effects, or impair 
metabolism/elimination of the test agent.29 It is difficult to detect 
a chemically induced response in an organ with a high 
spontaneous tumor rate.30 Both sexes of two species are typically 
used to identify any sex-specific responses and to confirm 
multiple species effects.31 
A major shortcoming of the rodent cancer bioassay is its 
limited statistical power to estimate the true response rate.32 
Power is the probability of detecting an effect (rejecting the null 
hypothesis33) when an effect exists; it is influenced by the 
                                                          
28 H.A. Solleveld et al., Natural History of Body Weight Gain, Survival, 
and Neoplasia in the F344 Rat, 72 J. NATL. CANCER INST., 929-40 (1984). 
29 G.N. Rao et al., Mouse Strains for Chemical Carcinogenicity Studies: 
Overview of a Workshop, 10 FUNDAMENTALS OF APPLIED TOXICOLOGY 385, 
385-94 (1988). 
30 Helmut Greim et al., Evaluation of Historical Control Data in 
Carcinogenicity Studies, 22 HUM. EXP. TOXICOL. 541, 541-49 (2003). 
31 See Bucher, supra note 8. 
32 Joseph K. Haseman, Statistical Support of the Proposed National 
Toxicology Program Protocol, 11 TOXICOLOGICAL PATHOLOGY 77, 77-82 
(1983). 
33 In this case, the null hypothesis is that there is no difference in 
response between exposed and unexposed animals. Rejection of the null 
hypothesis implies that an alternative hypothesis is more appropriate (i.e., the 
response is different in exposed versus unexposed animals). 
MELNICK 3/3/2007 2:06 AM 
120 JOURNAL OF LAW AND POLICY 
sample size, the background rate, and the magnitude of the true 
response.34 For example, in order to achieve statistical 
significance at the p≤0.05 level (i.e., the odds are 1 in 20 or less 
that a result occurred simply by chance) in a bioassay consisting 
of about 50 animals per sex and species per dose group, an 
incidence of 14 percent (7/50) or greater would be necessary in 
the exposed group if the incidence in the control group was two 
percent (1/50). Likewise, if the control incidence is 20 percent 
(10/50), the incidence in the treated group would need to be 38 
percent or greater (19/50) to achieve statistical significance at 
p≤0.05. However, if animal group size were only 25, then an 
incidence of 40 percent (10/25) would not be significant if the 
control incidence was still 20 percent (5/25). The power 
limitation of a study may lead to conflicting opinions when no 
changes or non-significant elevations in incidence are detected in 
treatment groups of small size. If the null hypothesis is not true 
(i.e., exposure produces an effect), the power of the study 
should be sufficiently large to allow rejection of that hypothesis. 
A negative, underpowered study provides no assurance of the 
absence of health risks in exposed populations. 
C.  Exposure 
Because of the limited statistical power of the bioassay when 
group size is only about 50 animals per sex per dose, high doses 
are typically used to identify potential carcinogenic hazards and 
multiple dose-groups are used to characterize dose-response 
relationships.35 Unless group size is extremely large (i.e., 
several hundred to thousands of animals per group), a negative 
carcinogenicity study (no statistically significant exposure-related 
effects) conducted at environmental exposure levels can lead to 
misinterpretation of the carcinogenic potential of an agent. For 
                                                          
34 Joseph K. Haseman, Statistical Issues in the Design, Analysis and 
Interpretation of Animal Carcinogenicity Studies, 58 ENVTL. HEALTH PERSP. 
385, 385-92 (1984). 
35 Richard A. Griesemer, Dose Selection for Animal Carcinogenicity 
Studies: A Practitioner’s Perspective, 5 CHEM. RES. TOXICOL. 737, 737-41 
(1992); Bucher, supra note 8. 
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example, if the true response rate at an environmental exposure 
level is 1 per 1000, then this exposure would not reveal a 
significant response if the animal group size is 50. However, 
environmental exposures associated with increased cancer risk of 
1 per 1000 in human populations would be dreadful. Data from 
preliminary studies, typically of 4 to 13 weeks duration, 
including evaluations of body weight changes, clinical 
observations, and pathological effects are used to estimate the 
maximally tolerated dose or the minimally toxic dose (MTD) for 
the subsequent cancer study.36 
The identification and use of an MTD is a critical aspect in 
the design of experimental carcinogenicity studies of low 
statistical power.37 The MTD should not cause increases in 
mortality other than from chemically induced tumors. Lower 
doses (one-half MTD and one-quarter to one-tenth MTD) are 
used if the high dose selected for the chronic study is found to 
be too high (excessive mortality) and to provide dose-response 
information.38 Pharmacokinetic information is also used to 
ensure that no more than one of the selected doses is above a 
level that saturates the processes of absorption, metabolic 
activation, or detoxification.39 In the absence of human data, the 
dose-response relationship in an experimental animal study 
serves as the basis for estimating risks at human exposure 
levels.40 A much better characterization of the true dose-
response can be achieved with several dose groups rather than 
                                                          
36 Victor A. Fung et al., The Carcinogenesis Bioassay in Perspective: 
Application in Identifying Human Cancer Hazards, 103 ENVTL. HEALTH 
PERSP. 680, 680-83 (1995). 
37 C.J. Portier & D.G. Hoel, Design of Animal Carcinogenicity Studies 
for Goodness-of-Fit of Multistage Models, 4 FUNDAMENTALS OF APPLIED 
TOXICOLOGY 949, 949-59 (1984). 
38 John R. Bucher et al., Workshop Overview, National Toxicology 
Program Studies: Principles of Dose Selection and Applications to 
Mechanistic Based Risk Assessment, 31 FUNDAMENTALS OF APPLIED 
TOXICOLOGY 1, 108 (1996). 
39 J.R. Buchanan et al., Purpose and Guidelines for Toxicokinetic Studies 
Within the National Toxicology Program, 105 ENVTL. HEALTH PERSP. 468, 
468-71 (1997). 
40 U.S. ENVTL. PROT. AGENCY, supra note 20. 
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only two widely spaced dose groups. 
Typical carcinogenicity studies in rats and mice involve 
exposures beginning at six weeks of age and continuing for two 
years; this exposure period corresponds roughly with early 
adulthood through most of an occupational life span.41 However, 
because of data indicating greater susceptibility with exposure to 
mutagens42 and endocrine disruptors43 during growth and early 
developmental stages, earlier periods of exposure are frequently 
included in animal carcinogenicity studies when fetal or 
childhood exposure to such agents might occur. The two-year 
duration limit was selected to minimize late-developing 
background tumor responses in controls as well as in animals 
exposed to the test agent that might preclude the detection of 
chemical-induced effects.44 Studies with exposure durations 
shorter than two years are also problematic because of their 
reduced sensitivity to detect increases in late-appearing tumors 
that are related to treatment with the test agent.45 
III.  EVALUATION ISSUES 
The conduct and evaluation of a cancer bioassay requires a 
multidisciplinary effort, including expertise from toxicologists, 
laboratory animal veterinarians, chemists, histologists, 
pathologists, cellular/molecular biologists, and statisticians. The 
interpretation of tumor data may be affected by the thoroughness 
of the histopathology evaluations, methods of statistical analysis, 
                                                          
41 Joseph K. Haseman et al., Carcinogenesis Bioassays: Study Duration 
and Biological Relevance, 39 FOOD & CHEMICAL TOXICOLOGY 739, 739-44 
(2001). 
42 J. M. Rice et al., Comparative Transplacental Carcinogenesis by 
Directly Acting and Metabolism-dependent Alkylating Agents in Rodents and 
Nonhuman Primates, 96 IARC SCI. PUBL. 17, 17-34 (1989). 
43 A.L. Herbst et al., Prenatal Diethylstilbestrol Exposure and Human 
Genital Tract Abnormalities, 51 NAT’L CANCER INST. MONOGRAPH 25, 25-35 
(1979). An endocrine disruptor is a natural or synthetic chemical that may 
mimic or antagonize the actions of natural hormones responsible for 
maintaining homeostasis and regulating development. 
44 Solleveld, supra note 28. 
45 Haseman, supra note 41. 
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and mechanistic considerations. With respect to human relevance 
of animal cancer data, the issue of concordance of the site of 
occurrence of the tumor has been raised; this topic is also 
discussed below. 
A.  Histopathology 
The detection of toxic effects and neoplastic lesions in 
animals depends on the thoroughness of the necropsies, or post-
mortem examinations of the animal, and the microscopic 
examinations performed on slides of tissue sections. The NTP 
requires examination of all organs and tissues, approximately 40 
per animal.46 In some cases, multiple sectioning of an organ in 
exposed and control groups may be necessary to obtain a truer 
estimate of the incidence of neoplastic lesions, especially for 
small lesions that may not be detected at necropsy.47 Although 
diagnostic criteria have been established for most observable 
lesions, it is not unusual for pathologists to disagree in their 
judgment of lesions, especially those that are part of a 
continuum of progressive change.48 After diagnoses by the study 
pathologist, all NTP studies undergo an independent quality 
assessment (QA) pathology review.49 This is followed by a 
pathology working group review (typically eight to ten 
pathologists) that seeks to resolve discrepancies in diagnoses 
between the original and the QA pathologists.50 Studies that lack 
multiple pathology evaluations may yield diagnostic data that 
would not be generally accepted. 
                                                          
46 Department of Health and Human Services, National Toxicology 
Program, http://ntp.niehs.nih.gov (last visited Dec. 15, 2006). 
47 S.L. Eustis et al., The Utility of Multiple-section Sampling in the 
Histopathological Evaluation of the Kidney for Carcinogenicity Studies, 22 
TOXICOLOGIC PATHOLOGY 457, 457-72 (1994). 
48 S.L. Eustis, The Sequential Development of Cancer: A Morphological 
Perspective, 49 TOXICOLOGY LETTERS 267, 267-81 (1989). 
49 G. A. Boorman et al., Quality Assurance in Pathology for Rodent 
Carcinogenicity Studies, in HANDBOOK OF CARCINOGEN TESTING 345, 345-57 
(H. Milman & E. Weisburger eds., 1985). 
50 Id. 
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In addition to statistical analyses described below, it should 
be recognized that other factors may contribute to the 
interpretation of tumor data, including: (1) the occurrence of 
uncommon versus common tumors, (2) evidence of progression 
of lesions, such as benign to malignant where it is appropriate to 
combine,51 (3) tumor occurrence with reduced latency, (4) 
multiplicity in a site-specific tumor response, (5) evidence of 
metastases, and (6) supporting evidence of proliferative 
preneoplastic lesions (lesions with high cell replication rates that 
may progress to tumors) at the same organ site or detection of 
the same lesion in the other sex or species. Because cancer 
development is a multi-step process with a long time period 
between exposure and manifestation of metastatic neoplasia, 
evidence of enhanced disease progression (e.g., reduced latency, 
tumor multiplicity, and metastasis) in an animal study is another 
indication that the agent promotes cancer development. 
B.  Statistics 
If mortality in a dose group is different from that of 
controls, it is important that pair-wise comparisons and analyses 
of trends be based on tumor rates that have been adjusted for 
deaths occurring before the end of the study.52 The reason for 
this survival-based adjustment is that if animals died early from 
causes other than tumors at the organ site of interest, then those 
animals would not have been on study long enough to provide a 
full contribution of risk to that study group. Failure to adjust for 
differences in survival will yield unreliable estimates of cancer 
risk, and possible misinterpretations of a true site-specific effect. 
Although comparisons between the concurrent control group 
and the exposure groups are the most valid for identifying 
chemically induced effects, comparisons with historical control 
                                                          
51 E. E. McConnell et al., Guidelines for Combining Neoplasms for 
Evaluation of Rodent Carcinogenesis Studies, 76 J. NAT’L CANCER INST. 283, 
283-89 (1986). 
52 Joseph K. Haseman, Statistical Issues in the Design, Analysis and 
Interpretation of Animal Carcinogenicity Studies, 58 ENVTL. HEALTH PERSP. 
385, 385-92 (1984). 
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data may also be helpful in interpreting treatment-related 
effects.53 For meaningful comparisons, the conditions of the 
current study must be similar to those in the historical database 
and diagnostic criteria must be identical. Thus, comparisons 
must be specific for the species, sex, and strain of animals, the 
route of exposure, and the diet. For example, dietary factors 
may influence animal survival, organ function, and spontaneous 
or chemically induced tumor rates. Conflicting interpretations of 
study findings may arise with improper use of historical 
databases. 
C.  Mechanistic Considerations 
Results from animal or in vitro studies that attempt to 
determine the mode-of-action for disease induction (i.e., 
mechanistic studies) have been used to upgrade or downgrade 
cancer risk classifications of agents that have inadequate or 
limited evidence in humans.54 For example, based on 
mechanistic data on early molecular and cellular events that 
likely contribute to cancer outcome, IARC and NTP upgraded 
ethylene oxide55 and 2,3,7,8-tetrachlorodibenzo-p-dioxin 
(TCDD)56 to “known human carcinogens.” In both cases, the 
evidence of carcinogenicity was limited in humans and sufficient 
                                                          
53 Joseph K. Haseman, Use of Historical Control Data in 
Carcinogenicity Studies in Rodents, 12 TOXICOLOGICAL PATHOLOGY 126, 
126-35 (1984). 
54 NAT’L TOXICOLOGY PROGRAM, supra note 10; 60 INT’L AGENCY FOR 
RESEARCH ON CANCER, Ethylene Oxide, in IARC MONOGRAPHS ON THE 
EVALUATION OF CARCINOGENIC RISKS TO HUMANS 73-159 (1994); 69 INT’L 
AGENCY FOR RESEARCH ON CANCER, 2,3,7,8-Tetrachlorodibenzo-para-
dioxin, in IARC MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS 
TO HUMANS 33-343 (1997). 
55 NAT’L TOXICOLOGY PROGRAM, supra note 10; 60 INT’L AGENCY FOR 
RESEARCH ON CANCER, Ethylene Oxide, in IARC MONOGRAPHS ON THE 
EVALUATION OF CARCINOGENIC RISKS TO HUMANS 73-159 (1994). 
56 NAT’L TOXICOLOGY PROGRAM, supra note 10; 69 INT’L AGENCY FOR 
RESEARCH ON CANCER, 2,3,7,8-Tetrachlorodibenzo-para-dioxin, in IARC 
MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS 33-
343 (1997). 
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in experimental animals. The upgrading of ethylene oxide was 
based largely on the induction of chromosomal aberrations in 
peripheral lymphocytes, micronuclei in bone marrow cells, and 
hemoglobin adducts in exposed workers.57 For TCDD, the 
upgrading was based on data demonstrating that the multi-site 
carcinogenicity of this chemical in experimental animals was due 
to a mechanism involving activation of the aryl hydrocarbon 
receptor and studies showing that this receptor is highly 
conserved across species and functions the same way in humans 
as it does in experimental animals.58 Thus, even though human 
epidemiological data alone were not sufficient to reach the 
“known human carcinogen” classification category, these 
authoritative bodies considered the combination of animal data 
and mechanistic data sufficient to support the upgraded “weight-
of-evidence” conclusions. The term “weight-of-evidence” is 
used by the EPA to reflect evaluations that are “based on the 
combined strength and coherence of inferences appropriately 
drawn from all of the available information.”59 
Similarly, one should be very concerned of the potential 
cancer risks for vinyl bromide (VBr) and vinyl fluoride (VF), 
because they are structural analogs of vinyl chloride, a known 
human carcinogen. Mechanistic data show that these three 
chemicals are metabolized to DNA-reactive intermediates by 
enzymes found in humans60 producing identical promutagenic 
DNA adducts. Experimental carcinogenicity studies show that 
these three chemicals induce multiple tumor types, including 
                                                          
57 NAT’L TOXICOLOGY PROGRAM, supra note 10; 60 INT’L AGENCY FOR 
RESEARCH ON CANCER, Ethylene Oxide, in IARC MONOGRAPHS ON THE 
EVALUATION OF CARCINOGENIC RISKS TO HUMANS 73-159 (1994). 
58 NATIONAL TOXICOLOGY PROGRAM, supra note 10; INT’L AGENCY FOR 
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MONOGRAPHS ON THE EVALUATION OF CARCINOGENIC RISKS TO HUMANS 33-
343 (1997). 
59 U.S. ENVTL. PROT. AGENCY, supra note 20, at 2-1. 
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RESEARCH IN TOXICOLOGY 168, 168-79 (1991). 
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angiosarcomas, in rats and mice.61 Because of these similarities, 
it would be unethical to require human data on VBr or VF 
before dealing with these chemicals as known human 
carcinogens. 
On the other hand, IARC downgraded the classification of 
di(2-ethylhexyl)phthalate (DEHP) from “possibly” to “not 
classifiable as to its carcinogenicity to humans.”62 The evidence 
of the carcinogenicity of DEHP was concluded to be sufficient 
in animals, based on increased incidences of liver tumors in rats 
and mice, and inadequate in humans.63 The downgrading of the 
animal cancer evidence was based on the panel’s acceptance of 
the hypothesis that DEHP induces liver tumors in rats and mice 
by a non-DNA-reactive mechanism involving an increase in the 
number of peroxisomes (subcellular structures that contain 
several oxidase enzymes). The tumor responses in rats and mice 
were considered to be irrelevant to humans because peroxisome 
proliferation had not been documented either in human 
hepatocyte cultures exposed to DEHP or in the liver of exposed 
non-human primates.64 However, peroxisome proliferation alone 
has not been shown to provide a reasonable mechanistic 
explanation for the different carcinogenic potencies of 
peroxisome proliferators in the rat liver.65 
Consequently, peroxisome proliferation may not be a reliable 
marker for evaluating human cancer risk. Other mode-of-action 
hypotheses for rodent liver tumor induction by peroxisome 
proliferators have not been tested. Thus, the mechanistic basis 
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for the IARC decision to downgrade DEHP66 is not supported 
by experimental evidence. Public health decisions that could lead 
to unrestricted use and exposure to carcinogenic agents should 
not rely on untested hypotheses.67 
D.  Site Concordance 
Differences in the organ or tissue in which tumors arise in 
animals and humans are one of the most contentious issues in 
the evaluation of the human relevance of experimental 
carcinogenicity data.68 This is largely due to the fact that the 
etiologies or causes of most cancers are not known and the bases 
for differences in species susceptibility are not fully 
understood.69 There are several examples in which human 
cancer sites correspond with one animal species, but not the 
second species (e.g., hematopoietic cancers induced by benzene 
in mice and humans, but not in rats) and there are also examples 
of site correspondence among rats, mice, and humans.70 
Although site correspondence may strengthen the animal-to-
human association, there are numerous reasons why that 
correspondence should not be a requirement for human 
relevance and causality. First, exposure factors might contribute 
to differences in sites of tumor induction, including the route, 
frequency, duration, intensity, as well as age at onset of 
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exposure.71 Exposure conditions are known to affect sites and 
dose-response for tumor induction in experimental studies. If 
gestational or early childhood exposure is important for tumor 
induction, then studies of male workers would not be expected 
to produce the same response as animal studies that include 
exposures during these stages of development. 
Second, there may not be an adequate human 
epidemiological study on the agent or an epidemiological study 
may not have detected a true increase in risk of certain cancers 
in exposed human populations due to inadequate exposure 
information, misclassifications, insufficient follow-up, and/or 
inadequate study power.72 
Third, human susceptibility to environmental carcinogens 
varies for a large number of reasons including genetic factors, 
health status, diet, lifestyle (e.g., smoking, alcohol 
consumption), age, and other exposures (e.g., medications, 
occupational experiences).73 Because cancer development is the 
likely result of interactions among environmental factors and 
individual susceptibility factors, differences in sites of tumor 
induction among individuals are not unusual for known human 
carcinogens. For example, although the lung is the most 
common cancer site among cigarette smokers, many people do 
not develop lung tumors but instead develop cancers of the 
bladder, kidney, nasal cavity, lip, esophagus, or pancreas. In 
some smokers no cancer is evident. Numerous host susceptibility 
factors could account for lack of site correspondence among 
individuals in exposed populations or between experimental 
animals and humans. 
Because of the much greater genetic diversity in humans 
compared to strains of laboratory animals, the range of expected 
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human response may include subgroups that are less, equal, or 
more sensitive than the animal models used in the experimental 
cancer studies. Unless a qualitative difference between animals 
and humans is clearly shown to be the determinant of a species-
specific cancer response, it is prudent to assume that a 
carcinogenic effect in animals is a reliable indicator of potential 
cancer risk in humans. This perspective has been endorsed by 
major national and international public health agencies that 
evaluate human cancer risks associated with exposures to 
environmental and occupational agents.74 
IV.  ESTIMATING HUMAN CANCER RISK FROM ANIMAL DATA 
Risk assessment provides a systematic approach for 
characterizing the nature and probability of adverse effects (i.e., 
health risks) occurring in individuals or populations exposed to 
hazardous agents and often serves as the basis for risk 
management decisions on whether and to what extent human 
exposure to such agents should be controlled. The National 
Academy of Sciences/National Research Council (NAS/NRC) 
developed guidelines for the conduct of risk assessments in the 
federal government.75 The risk assessment paradigm developed 
by the NAS/NRC consists of four parts: hazard identification, 
dose-response assessment, exposure assessment, and risk 
characterization.76 
When adequate human data is not available, dose-response 
data from studies in laboratory animals serve as the basis for 
estimating risks in exposed humans.77 A quantitative risk 
assessment requires conversion of animal doses to human 
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equivalent doses.78 If a verified physiologically based 
pharmacokinetic model is available for the specific agent, this 
might be used to describe the internalized dose in humans by 
replacing animal physiological and biochemical parameters in the 
model with those specific for humans (e.g., breathing volumes, 
organ sizes, cardiac output, metabolic rate constants, etc.). 
Computer-based dosimetry models consist of a series of 
mathematical equations that represent, in quantitative terms, the 
complex biological processes that affect the absorption, 
distribution, metabolism, and elimination of the agent in the 
intact animal. These models can accommodate parameter values 
that represent the range and distribution of activities that exist in 
human populations. Reliable models can provide estimates of 
tissue dose as a function of duration and frequency of exposure 
to various environmental exposure levels.79 However, one must 
be cautious of assumptions in models that have not been 
validated because they could lead to inaccurate estimates of 
tissue dose. If a verified dosimetry model is not available, 
human equivalent exposures are typically obtained by scaling 
animal doses to humans as a function of body surface area (i.e., 
body weight to the ¾ power).80 The assumption in this approach 
that metabolic activities differ among species according to body 
surface area may not be true. 
The next step in the risk assessment process is to fit 
empirical models (or mechanistic-based models if the mechanism 
of the disease induction is known) to the dose and cancer 
incidence data corrected for background and then to determine 
which model provides the best fit to the dose-response data. 
By extending the dose-response curve, it is possible to 
estimate the cancer risk at human exposure levels, or to estimate 
the exposure levels that are associated with specific risks (e.g., 
one per hundred, one per thousand, one per million). In their 
most recent cancer risk assessment guidelines, the EPA 
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recommends modeling dose-response data to determine the 
effective dose associated with one percent (ED01) or 10 percent 
(ED10) risk and the lower 95 percent limit on those dose 
estimates (LED01 or LED10).81 From this point a straight line is 
drawn to zero risk for mutagenic carcinogens or chemicals for 
which the mode-of-action has not been characterized. Cancer 
risks at lower exposure levels are estimated from the slope of 
this line. These risks can then be compared to age, sex, and 
race-dependent incidences of specific cancers in the U.S. 
population reported in the Surveillance, Epidemiology, and End 
Results (SEER) data set82 to determine the relative risk of 
developing or dying from cancer due to a particular exposure. 
Relative risk is the incidence of disease in an exposed population 
divided by the incidence of that disease in the unexposed 
population.83 
For example, consider women working at a facility where 
they are exposed until age 60 to a carcinogen at a level 
associated with additional leukemia risk of 1.5 per thousand. 
Since the probability of women in the general U.S. population 
dying from leukemia by age 60 is 1.25 per thousand, then the 
relative risk of dying from leukemia due to that exposure is 2.2. 
The estimated incidence in the unexposed population is 
1.25/1000, while the estimated incidence in the exposed 
population is the background risk (1.25/1000) plus the additional 
risk associated with exposure (1.5/1000). Relative risk equals 
(0.00125 + 0.0015)/0.00125 = 2.2. 
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CONCLUSION 
Data from properly designed and evaluated studies in 
experimental animals have been and continue to be reliable 
sources of information for the identification of potential human 
health hazards and the estimation of risks in exposed 
populations. Properly designed animal studies must include: (1) 
animal models that are sensitive to the endpoints under 
investigation, (2) detailed characterization of the agent and the 
administered doses, (3) challenging doses (MTD) and durations 
of exposure (at least two years for rats and mice) that would 
allow a reliable determination of whether or not the agent poses 
a health hazard, (4) sufficient numbers of animals per dose 
group to have adequate statistical power to detect a true effect, 
(5) multiple dose groups to allow characterization of dose-
response relationships, (6) complete and peer-reviewed 
histopathological evaluations, and (7) pair-wise comparisons and 
analyses of trends based on survival-adjusted tumor rates. 
Mechanistic information and pharmacokinetic models that have 
been adequately tested may impact the characterization of dose-
response relationships. Until the etiology of environmentally 
induced cancers and the basis for human susceptibility are better 
understood, site correspondence should not be a requirement for 
judging human relevance and causality. 
 
